Report
Cancer drugmakers that paid fines or settlements rarely admitted wrongdoing
ICIJ says some companies explained settlements as a way to avoid lengthy, expensive litigation.
TLDR
An ICIJ analysis found that cancer drug companies that paid fines or made settlement payments rarely admitted wrongdoing. When companies settled, their explanations sometimes centered on avoiding lengthy, expensive litigation.
Combined views
—
1 Source, first seen ago